Feature Catalyst Trade Alert: We bought Antares (ATRS) Shares. We feel Antares price will recover nicely heading into this month’s expected PDUFA date in the middle of October, and feel any gov shutdown will be short-lived and not effect the…
Month: September 2013
A Video Review of Last Week and The Week Ahead, 9/30/13
A Video Review of Last Week and The Week Ahead, 9/30/13. Chart reviews of $ACRX, $ATRS, $SLTM, $HALO + My commentary on The Budget debate and what to expect in the upcoming week ahead! May all your investments and trades…
5 Biopharmas With Upcoming Catalysts That Should Rally
Today, StockMatusow highlights five companies with near-term catalysts along with positive sentiment that we feel could significantly see much higher stock prices in the short-term. As we move out of September and into October, the market historically sees increased in-flows…
Edited: Is An Acquisition Of Solta Medical Imminent?
In my last article concerning Solta Medical Devices (SLTM), I remarked several times how I feel the company has good assets and the potential to grab significant market share in various segments. However, I do feel the company and its…
FIXED: (everyone can see this now) Video: Market Commentary For Week Sept 23 – 2013 ( One Day Public Preview)
Released to Premium Subscribers on Sunday, September 22. Public Preview for one day, to get an idea of our premium service. Market Commentary For Week Sept 23 – 2013. $ATRS $ACRX $SLTM $HALO $IDRA. Market forecast for upcoming week, Merkel…
Video: AcelRx (ACRX) Chart Analysis + Insider Sell Explained – Sign of Acquisition Soon
AcelRx (ACRX) Chart Analysis + Insider Sell Explained – Sign of Acquisition Soon. Give it a good listen as I will explain why the insider sell is actually a likely sign of an acquisition. I also give chart analysis and…
David Callan’s Letter to Solta Medical
September 5, 2013 Solta Medical, Inc. Attn: Members of the Board of Directors 25881 Industrial Boulevard Hayward, CA 94545 Ladies and Gentlemen: This is my second letter to the board. My first letter went without response or acknowledgement, as…
Video: Halozyme 60 Minute, 10 Day Chart Analysis As Of Close, 9/16/13 – Sentiment = Bullish
Halozyme 60 Minute, 10 Day Chart Analysis As Of Close, 9/16/13 – Sentiment = Bullish
$HALO Analyst excerpt report $13 Price Target -Outperform
Halozyme Therapeutics (HALO-NASDAQ) Stock Rating: Outperformï€ Industry Rating: Outperform September 3, 2013 Biotechnology Jim Birchenough, M.D. BMO Capital Markets Corp. 415-591-2129 jim.birchenough@bmo.com Chuck Whitesell / Nick Abbott, PhD HERCEPTIN SC Approval Should Support Rapid Switch Opportunity Event HALO partner Roche…
Catalyst Trade Call Alert – $HALO – Target opinion = $10
Trade Call Alert – $HALO – Target opinion = $10. Catalyst = “As per agreed criteria, the PRAC endorsed without further planary discussion the conclusions of the Rapporteur on the assessment of this updated 9.1 of the RMP for the…